Pyrazole, Pyrazoline, and Fused Pyrazole Derivatives: New Horizons in EGFR‐Targeted Anticancer Agents
Bibliographic record
Abstract
Pyrazole and its derivatives remain popular heterocycles in drug research, design, and development. Several drugs include the pyrazole scaffold, such as ramifenazone, ibipinabant, antipyrine, and axitinib, etc. They have been extensively studied by the scientific community and are said to have a wide range of biological activity, especially anticancer agents targeting EGFR. Overexpression of EGFR signalling promotes tumor growth by inhibiting apoptosis. EGFR dysfunction has been described in multiple cancers, including colon, head and neck, NSCLC, colon, liver, breast, and ovarian cancer. As a result, EGFR represents a prospective target for cancer treatment. Several anti-EGFR drugs are thriving, notably dacomitinib, afatinib, erlotinib, gefitinib, and osimertinib. However, almost all currently available anti-EGFR drugs have limited therapeutic effectiveness due to a lack of selectivity as well as substantial side effects. Furthermore, aberrant EGFR signalling across numerous human malignancies/carcinomas is impeded by gene amplification, protein overexpression, mutations, or in-frame deletions, making EGFR-induced cancer treatment challenging. To overcome such, novel therapeutic anti-EGFR drugs with high efficacy and minimal toxicity are required. To battle cancer and therapeutic resistance to EGFR inhibitors, pyrazole, pyrazoline, and their derivatives have been investigated as a viable pharmacophore for the development of new drugs with better potency, lesser toxicity, and favourable pharmacokinetic characteristics. The present investigation covers the examination of progress toward anti-cancer therapies targeting EGFR via pyrazole, pyrazoline, and fused pyrazole-based compounds. The current study also represents inclusive data on pyrazole-based marketed drugs as well as therapeutic candidates undergoing preclinical and clinical development. Lastly, we have discussed recent advances in the medicinal chemistry of pyrazole-based derivatives with their anti-EGFR significance for the eradication of various cancers and provide the direction toward structure-activity relationship (SAR), including mechanistic studies.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.001 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.002 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".